10-K: Arteris, Inc. Reports Fiscal Year 2024 Results, Highlights Growth in Annual Contract Value

Arteris, Inc. reports increased revenue and Annual Contract Value (ACV) for fiscal year 2024, while still incurring a net loss as it invests in future growth.

Summary

• Arteris, Inc. reported its financial results for the fiscal year ended December 31, 2024.
• The company's revenue increased to $57.7 million, compared to $53.7 million in 2023.
• Despite the revenue growth, Arteris incurred a net loss of $33.6 million, a slight improvement from the $36.9 million loss in the previous year.
• The company's Annual Contract Value (ACV) reached $60.7 million, and ACV plus royalties totaled $65.1 million as of December 31, 2024.
• Arteris added 10 net new Active Customers during the year.
• The company expects to incur further net losses in the short term as it continues to invest in its business.
• Research and development expenses accounted for 78% of revenue in 2024, totaling $45.0 million.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. Revenue and ACV are up, indicating growth, but the company is still operating at a loss and investing heavily in R&D. The outlook is cautiously optimistic, but there are significant risks to consider.

Positives

• Revenue increased by 8% year-over-year.
• Annual Contract Value (ACV) increased to $60.7 million.
• The company added 10 net new Active Customers.
• Net loss decreased slightly compared to the previous year.

Negatives

• The company incurred a net loss of $33.6 million.
• Research and development expenses remain high at 78% of revenue.

Risks

• The company faces significant competition from larger companies.
• The company may not achieve or maintain profitability in the future.
• The company depends on market acceptance of third-party semiconductor IP.
• The company is subject to government regulation, including import, export and economic sanctions laws and artificial intelligence regulations that may expose it to liability and increase its costs.
• The company faces risks associated with doing business in China.
• The company is currently involved in ongoing litigation related to patent infringement claims.

Future Outlook

The company expects to incur further net losses in the short term as it invests in its business. The company expects R&D expenses to increase in absolute terms and as a percentage of revenue in the short term and to continue to increase in absolute terms in the medium to long term but decrease as a percentage of revenue as certain new products are launched. The company expects S&M expenses to increase in absolute terms but decrease as a percentage of revenue due to productivity improvements of our sales processes.

Industry Context

The company operates in the semiconductor IP market, which is characterized by rapid technological change and increasing levels of integration. The company's growth is tied to the increasing complexity of SoCs and the growing demand for third-party IP solutions. The company is focused on high-growth markets, including automotive, enterprise computing, consumer electronics, communications, and industrial.

Comparison to Industry Standards

• It's difficult to provide a direct comparison to industry standards without knowing the specific details of Arteris' contracts and product mix.
• However, companies like ARM also operate in the IP licensing space, and their financial performance can be used as a general benchmark.
• ARM's licensing revenue is often driven by similar factors, such as the adoption of new technologies and the growth of key end markets.
• Comparing Arteris' ACV and royalty rates to those of ARM and other competitors would provide a more detailed assessment of its performance relative to industry standards.
• The company's high R&D spending as a percentage of revenue is typical for companies in the semiconductor IP space, as they need to continuously innovate to stay competitive.

Legal Proceedings

• The company is currently involved in ongoing litigation related to patent infringement claims.

Related Party Transactions

• The company entered into a lease agreement with Isabelle Geday, a member of the Board of Directors.
• The company signed a consulting agreement with Ms. Geday on December 1, 2021, which was subsequently assigned to Magillem Design Services S.A., effective January 10, 2022.
• On November 15, 2024, the company entered into a design services licensing business collaboration agreement with Transchip.

Stakeholder Impact

• Shareholders: The company's stock price may be volatile, and investors may not be able to resell shares at or above the price paid.
• Employees: The company depends on key and highly skilled personnel to operate its business, and if it is unable to retain its current personnel and hire additional personnel, its ability to develop and market its products could be harmed.
• Customers: The company's ability to offer high-quality support is critical for the successful deployment of its IP in its customers designs.
• Suppliers: The company's supply chain may become more complex due to social and environmental responsibility regulations, policies and provisions, as well as customer and investor demands.

Next Steps

• The company plans to continue investing in research and development.
• The company plans to continue expanding its sales force, both domestically and internationally.
• The company plans to dedicate significant resources to sales and marketing programs.
• The company plans to continue to pursue selective acquisitions and other strategic transactions, such as joint ventures, to acquire complementary solutions and accelerate growth.

Key Dates

Keywords

Annual Contract Value, System IP, NoC, Interconnect IP, Semiconductor, Revenue, ACV, Arteris